Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests: A study in 9 Swiss laboratories
Open Access
- 30 April 2012
- journal article
- research article
- Published by Elsevier BV in Thrombosis Research
- Vol. 129 (4), 492-498
- https://doi.org/10.1016/j.thromres.2011.06.031
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Rivaroxaban: A New Oral Factor Xa InhibitorArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasmaThrombosis and Haemostasis, 2010
- Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assayThrombosis and Haemostasis, 2010
- Rivaroxaban – an oral, direct Factor Xa inhibitor – lessons from a broad clinical study programmeEuropean Journal of Haematology, 2009
- Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal functionJournal of Thrombosis and Haemostasis, 2009
- A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein–DVT Dose-Ranging StudyBlood, 2008
- Determination of rivaroxaban – a novel, oral, direct Factor Xa inhibitor – in human plasma by high-performance liquid chromatography–tandem mass spectrometryJournal of Chromatography B, 2008
- Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacementThrombosis and Haemostasis, 2008
- Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939)Circulation, 2007
- Assessing intrarater, interrater and test–retest reliability of continuous measurementsStatistics in Medicine, 2002